Navigation Links
Mouse Study Hints at New Path for Diabetes Treatment
Date:4/12/2012

By Serena Gordon
HealthDay Reporter

THURSDAY, April 12 (HealthDay News) -- A potential new treatment for type 2 diabetes targets the hormone glucagon instead of insulin, according to a new study in mice.

Although the research hasn't yet progressed past animal models of the disease, initial results suggest that the novel therapy can lower blood sugar, decrease insulin resistance, lower cholesterol and help keep fatty deposits from settling in the liver.

What's more, the researchers didn't see any adverse effects from the treatment.

"A new target for the adverse effects of glucagon on diabetes has been identified, and with treatment we got rid of all the bad stuff, but didn't cause side effects," said the study's lead author, Dr. Ira Tabas, a distinguished professor of medicine at Columbia University Medical Center, in New York City.

Results of the study are published in the April 12 online edition of Cell Metabolism.

Glucagon is a hormone whose main role is to protect the body and brain from low blood-sugar levels during periods of fasting, such as overnight. It is produced by the alpha cells in the pancreas, Tabas said. When the alpha cells in the pancreas sense dropping blood sugar and insulin levels, they secrete glucagon, which in turn, causes the liver to produce glucose to feed the brain and body.

Normally, glucagon only kicks in when you're starving, because it senses low insulin levels. But, in type 2 diabetes, the body becomes resistant to insulin, so even though insulin is present, the liver thinks the body has no glucose because the insulin isn't helping get glucose into the body's cells the way it should, Tabas explained. That causes the liver to send out a signal for glucagon, and then the liver releases more sugar. "It just turns into a horrible feedback cycle," he said.

Commenting on the study, Dr. Vivian Fonseca, president of medicine and science at the American Diabetes Association, explained that "when you eat a meal and your sugar goes up, glucagon and glucose should switch off, but that doesn't happen in type 2 diabetes."

Currently, type 2 diabetes treatments focus on replacing insulin or making insulin work more effectively (known as improving insulin sensitivity). But, finding a way to block some of the action of glucagon might also help control type 2 diabetes.

The problem is that because glucagon serves a vital function in keeping the brain and body nourished with glucose in times of fasting, scientists can't make a drug that completely suppresses the action of glucagon.

In addition to the brain not getting enough sugar, early research that just partially blocked glucagon caused weight gain, fatty liver deposits and increased cholesterol. Tabas said it's still not entirely clear why partially blocking glucagon caused these effects.

Clearly, a different approach was needed. So, rather than trying to block glucagon, Tabas and his colleagues followed glucagon's pathways.

"Imagine if you have five pathways: A, B, C, D and E. Blocking pathways A and B can stop diabetes. But, if you block C, D, and E, you cause bad effects. So, you have to move further downstream to find the molecules that are responsible for pathways A and B so you can block those without blocking C, D, and E," Tabas explained.

"The more specific you can get, the less likely you'll have adverse effects," he added.

The pathway they found is an enzyme called CaMKII, and Tabas said this particular pathway is also being studied in inflammatory diseases, such as arthritis and asthma, because inhibiting this enzyme seems to lower inflammation as well.

When the researchers blocked CaMKII in obese mice bred to have diabetes, their blood sugar went down, insulin sensitivity improved, cholesterol decreased and fatty liver improved. And, there was no evidence of adverse effects from blocking CaMKII.

"There's always a concern whenever you inhibit any molecule in the body. We need to know why it's there naturally and what could be the possible effects of inhibiting it. Our study showed no specific concerns though," Tabas said.

While the findings of the new study are promising, scientists note that research involving animals often fails to produce similar results in humans.

For her part, Fonseca said, "This is an interesting and exciting scientific finding on how glucagon works, and it provides a new treatment target. But, it's in the very early stages of research."

More information

Learn more about currently available treatments for type 2 diabetes from the American Diabetes Association.

SOURCES: Ira Tabas, M.D., Ph.D., Richard J. Stock professor of medicine, Columbia University Medical Center, New York City; Vivian Fonseca, M.D., president, medicine and science, American Diabetes Association; April 12, 2012, Cell Metabolism, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Rapamycin rescues learning, memory in Alzheimers mouse model
2. NIA researchers find gene to explain mouse embryonic stem cell immortality
3. Dxtra Introduces New Solid Stainless Steel Mouse Pad
4. UCSF Transgenic Mouse Mimics Parkinson's Earliest Symptoms
5. McGill-UBC project creates mouse grimace scale to help identify pain in humans and animals
6. Fat in Males, Females Differs Genetically, Mouse Study Shows
7. Ergonomic HandShoe Mouse Publish Proof of Unique Difference with Competition
8. Rheumatoid arthritis signaling protein reverses Alzheimers disease in mouse model
9. Treatment for S. aureus skin infection works in mouse model
10. Mouse Study May Help Explain Fish Oils Benefits
11. Mouse Study Reveals a Cancer Cell Escape Route
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mouse Study Hints at New Path for Diabetes Treatment
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an ... 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages with a ... . Dr. Schwarz’s success is reflected in the superior patient reviews that he has ...
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading ... 11 innovative workshops and training opportunities in the growing field of yoga ... individuals who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic ...
(Date:5/25/2016)... ... ... Cheryl Bowker of Bowker Insurance Group has been presented with one of the ... ran one of Allstate’s most successful agencies for 48 years, but it was his ... award named for him is not given every year, but only when an agency ...
(Date:5/25/2016)... ... 25, 2016 , ... The Global Wellness Summit (GWS) today announced that its ... of Europe, a continent that pioneered the medical/wellness concept for the world. , Delegates ... medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness centers ...
(Date:5/25/2016)... ... May 25, 2016 , ... TransactRx announces the release of ... medical service claims by Pharmacy Benefit Managers that were submitted by Retail Clinics ... TransactRx Cross Benefit Clearinghouse receives standard professional medical claims submitted from the retail ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... Markt gebracht, die es Ärzten erlaubt, ihre Expertise ... behandeln: MDLinking kombiniert Live Streaming mit einer Instant-Messaging-Funktion ... zu kommunizieren. Mediziner in Europa, Afrika, Asien und ... bereits für die Plattform registriert. Information ...
(Date:5/24/2016)... Nev. , May 24, 2016  Diana Russell ... "eats" her organs from the inside out.  This disease ... completely dependent on her children and grandchildren to leave ... her wheelchair, Diana,s family cannot haul the wheelchair.  So ... in the car, and Diana is left to wait ...
(Date:5/24/2016)... 24, 2016  Joe Marziani has joined VMS BioMarketing as senior vice president of ... In his new role, Marziani will lead the company,s business development and sales team, ... outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: